You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

RIMEGEPANT SULFATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for rimegepant sulfate and what is the scope of freedom to operate?

Rimegepant sulfate is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rimegepant sulfate has one hundred and six patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for RIMEGEPANT SULFATE
International Patents:106
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 2
What excipients (inactive ingredients) are in RIMEGEPANT SULFATE?RIMEGEPANT SULFATE excipients list
DailyMed Link:RIMEGEPANT SULFATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RIMEGEPANT SULFATE
Generic Entry Date for RIMEGEPANT SULFATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for RIMEGEPANT SULFATE
Paragraph IV (Patent) Challenges for RIMEGEPANT SULFATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NURTEC ODT Orally Disintegrating Tablets rimegepant sulfate 75 mg 212728 7 2024-02-27

US Patents and Regulatory Information for RIMEGEPANT SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Pfizer NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Pfizer NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for RIMEGEPANT SULFATE

Country Patent Number Title Estimated Expiration
Cyprus 1122121 ⤷  Sign Up
Brazil 112014021032 ⤷  Sign Up
Canada 2777518 ANTAGONISTES DE RECEPTEUR CGRP (CGRP RECEPTOR ANTAGONISTS) ⤷  Sign Up
Brazil 112020019396 rimegepant para distúrbios relacionados a cgrt ⤷  Sign Up
Peru 20121137 ANTAGONISTAS DEL RECEPTOR DE CGRP ⤷  Sign Up
Canada 3094693 RIMEGEPANT POUR TROUBLES LIES AU CGRP (RIMEGEPANT FOR CGRP RELATED DISORDERS) ⤷  Sign Up
Taiwan 201118096 CGRP receptor antagonists ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for RIMEGEPANT SULFATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2488512 LUC00272 Luxembourg ⤷  Sign Up PRODUCT NAME: RIMEGEPANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1645 20220426
2488512 PA2022516 Lithuania ⤷  Sign Up PRODUCT NAME: RIMEGEPANTAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/22/1645 20220425
2488512 CA 2022 00036 Denmark ⤷  Sign Up PRODUCT NAME: RIMEGEPANT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1645 20220426
2488512 122022000048 Germany ⤷  Sign Up PRODUCT NAME: RIMEGEPANT ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1645 20220425
2488512 C02488512/01 Switzerland ⤷  Sign Up PRODUCT NAME: RIMEGEPANT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69035 18.10.2023
2488512 22C1044 France ⤷  Sign Up PRODUCT NAME: RIMEGEPANT OU UN SEL ACCEPTABLE SUR LE PLAN PHARMACEUTIQUE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/22/1645 20220426
2488512 33/2022 Austria ⤷  Sign Up PRODUCT NAME: RIMEGEPANT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1645 (MITTEILUNG) 20220426
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.